Advertisements


Roche"s Child Arthritis Drug"s New Formulation Gets FDA Nod

Zacks.....»»

Category: topSource: redinewsSep 14th, 2018

Roche Gets FDA Approval for New Formulation of Asthma Drug

Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair. Roche Holding AG RHHBY announced that the FDA has approved expansion prefilled .....»»

Category: dealsSource: nytOct 1st, 2018

AbbVie expects double-digit earnings growth in 2019

AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union......»»

Category: topSource: reutersNov 2nd, 2018

Biogen (BIIB) Q3 Earnings Coming Up: What"s in the Cards?

On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance. Biogen Inc. BIIB will report third-quarter 2018 re.....»»

Category: smallbizSource: nytOct 19th, 2018

FDA Accepts Application for AbbVie"s Imbruvica in Specific Blood Cancers

The drug will be used together with Roche's GazyvaRelated Stocks: ABBV, XSWX:RO,.....»»

Category: dealsSource: nytOct 18th, 2018

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) read more.....»»

Category: blogSource: benzingaOct 17th, 2018

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP) Krys.....»»

Category: earningsSource: benzingaOct 17th, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatm.....»»

Category: smallbizSource: nytOct 10th, 2018

Ionis"s stock surges after Roche collaboration, which could be worth up to $759 million

Shares of Ionis Pharmaceuticals Inc. rallied 4.7% in premarket trade, after the drug discovery company announced a new collaboration deal with Switzerland-based Roche Holding AG , which could be.....»»

Category: topSource: marketwatchOct 10th, 2018

Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam

Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on ris.....»»

Category: dealsSource: nytOct 4th, 2018

PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 3rd, 2018

Halozyme: Roche receives approval for subcutaneous formulation of trastuzumab

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2018

Roche CEO says Brexit, drug regulation threaten U.K. science, Reuters says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2018

Gilead"s Rheumatoid Arthritis Drug Successful in Phase III

Zacks.....»»

Category: topSource: redinewsSep 12th, 2018

Gilead"s Rheumatoid Arthritis Drug Successful in Phase III

Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secon.....»»

Category: worldSource: nytSep 12th, 2018

The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead"s Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC) Genomic Heal.....»»

Category: earningsSource: benzingaSep 12th, 2018

The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead"s Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) read more.....»»

Category: blogSource: benzingaSep 12th, 2018

Drug succeeds in arthritis study, Gilead stock jumps

A new drug meant to help rheumatoid arthritis achieved .....»»

Category: topSource: marketwatchSep 11th, 2018

Roche faces U.K. pricing row over multiple sclerosis drug, Reuters says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 9th, 2018

Roche faces UK pricing row over multiple sclerosis drug Ocrevus

Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS)......»»

Category: topSource: reutersSep 9th, 2018